Ipsen S.A. (0MH6.L)
| Previous close | 92.95 |
| Open | 92.55 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 92.55 - 92.55 |
| 52-week range | 92.55 - 92.55 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP
Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP PDUFA date has been set for 16 August 2023 following the New Drug Application resubmission containing additional information on palovarotene clinical trial data, requested in a complete response letter to Ipsen in December 2022 PARIS, FRANCE, 16 March 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA)
- Globe Newswire
Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 28 February 2023 83,814,526 Gross total* of voting rights: 132,091,376 Net tot
- Globe Newswire
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio Bringing medicines to patients with rare liver disease, a growth opportunity for IpsenLead asset Bylvay® (odevixibat) is the first approved treatment in progressive familial intrahepatic cholestasis, with two additional investigational indications in rare, pediatric liver diseases Acquisition adds novel bile-acid modulators and an innovative pipeline to the existing rare liver portfolio PARIS, FRANCE, 3 Mar
